The role of passive immunization in HIV-positive patients: A case report

Chest

Volumn 120, Issue 2, 2001, Pages 662-666

  Veljkovic, Veljko ^a   Metlas, Radmila ^b   Jevtovic, Djorde ^c   Stringer, William W ^d  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b G   (United Kingdom)

^c Institute for Infectious and Tropical Diseases   (Serbia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aerobic exercise; AIDS; Anti vasoactive intestinal peptide NTM antibodies; HIV; Ig preparations; Passive immunization; Tuberculosis

Indexed keywords

CD4 IMMUNOGLOBULIN; FRESH FROZEN PLASMA; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; VASOACTIVE INTESTINAL POLYPEPTIDE ANTIBODY; ZIDOVUDINE;

AGED; ANTIBODY TITER; ARTICLE; BLOOD DONOR; CASE REPORT; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG MECHANISM; EXERCISE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; LUNG TUBERCULOSIS; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034837728     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.2.662     Document Type: Article

References (37)

1. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome
2. Polymerase chain reaction evidence for HIV-1 neutralization by passive immunization in patients with AIDS and AIDS-related complex
3. Prevention of HIV infection by passive immunization with HIV immunoglobulin
4. Preparation and characterization of an intravenous solution of Ig from human immunodeficiency virus-seropositive donors
5. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection
6. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: Results of a 12-month multicenter double-blind controlled trial
7. PASSHIV-1 treatment of patients with HIV-1 infection: A preliminary report of a phase-1 trial of hyperimmune porcine immunoglobulin to HIV-1
8. Search for epitope-specific antibody responses to the HIV-1 envelope glycoprotein signifying resistance to disease development
9. Mapping of IgG subclass and T-cell epitopes on HIV proteins by synthetic peptides
10. Spectral and sequence similarity between VIP and the second conserved region of HIV envelope glycoprotein gp120: Possible consequences on prevention and therapy of AIDS
11. Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120
12. Human autoantibody to vasoactive intestinal peptide: Increased incidence in muscular exercise
13. Deceptive imprinting in the immune response to HIV-1 infection
14. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization
15. Identification of nanopeptide from HTLV-III, ARV-2 and LAV envelope gp120 determining binding of T4 cell surface protein
16. CD4-binding regions of human immunodeficiency virus envelope glycoprotein gp120 defined by proteolytic digestion
17. Cloning and characterization of human immunodeficiency virus type I variants diminished in the ability to induce syncytium-independent cytolysis
18. Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-formation ability
19. Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: Evidence for multiple pathways
20. Antigenic analysis of HIV type 1 external envelope (Env) glycoprotein C2 region: Implications for the structure of Env
21. Catalytic hydrolysis of vasoactive intestinal peptide by human antibody
22. Natural catalytic immunity is not restricted to autoantigenic substrates
23. HIV and idiotypic T-cell regulation: Another view
24. Does HIV-1 gp120 manipulate humane immune network
25. Characterization of HIV-1 neutralization escape mutants
26. Enhancement of human immunodeficiency virus type 1 (HIV-1) infection by antisera to peptide from the envelope glycoprotein gp120/41
27. Potential risk of eliciting antibodies enhancing HiV-1 infection of monocytic cells by vaccination with v3 loop of HIV-1 isolates
28. Enhancing antibody in HIV infection
29. A human anti-HIV autoantibodies enhances EBV transformation and HIV infection
30. Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera
31. Anti-V3 and anti-IgG antibodies of healthy individuals share complementary structures
32. AIDS epidemic at the beginning of third millennium: Time for a new AIDS vaccine strategy
33. Increase in plasma vasoactive intestinal polypeptide (VIP) in muscular exercise in humans
34. Human gastrin and vasoactive intestinal polypeptide responses to endurance running in relation to training status and fluid ingested
35. HIV and aerobic exercise: Current recommendations
36. The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients